Atopic Dermatitis study: Tilrekimig
Official title A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
ClinicalTrials.gov ID: NCT07765888
What this study is testing
What is Tilrekimig?
An investigational subcutaneous injectable medicine being studied for moderate to severe atopic dermatitis (eczema).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether Tilrekimig works well and is safe when used with skin creams for eczema.
- Who it's for
- You may be able to join if you are 12 or older, have eczema for at least a year, and your doctor says it is moderate or severe.
- What's involved
- You will receive either Tilrekimig or a pretend treatment. You will use the medicine at home and visit the clinic for check‑ins and tests.
- Time commitment
- The main study lasts 24 weeks with visits every few weeks, and you may be invited to a longer follow‑up study after week 24.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- Participants 12 years of age or older
- Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 12 months prior to Day 1
- An inadequate response to standard of care treatments {eg, at least medium potency topical corticosteroids (TCS)} consistent with AD treatment...
- Moderate-to-severe eczema for at least 1 year
- Adolescent participants must be up to date on immunizations per local guidance.
You likely can't join if
- Clinically Significant Autoimmune Disease
- Significant Infection History or Active Infection
- Known or Suspected Immunodeficiency/Immunosuppression
- Significant psychiatric illness or suicidality
- Clinically significant hepatic, renal, or hematologic abnormalities
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Scottsdale, Arizona, United States
- Bakersfield, California, United States
- Northridge, California, United States
- San Diego, California, United States
- Miami, Florida, United States
- Panama City, Florida, United States
- St. Petersburg, Florida, United States
- Marietta, Georgia, United States
- Savannah, Georgia, United States
- Fargo, North Dakota, United States
- Dallas, Texas, United States
- Southlake, Texas, United States
- Montreal, Quebec, Canada
- Matsudo, Chiba, Japan
- Nagaoka, Niigata, Japan
- Sakai, Osaka, Japan
- Shinagawa, Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Scottsdale, Arizona, United States; Bakersfield, California, United States; Northridge, California, United States; San Diego, California, United States; Miami, Florida, United States and 12 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.